Newsletter Tool

To view this email as a web page, click here

Today's Rundown

CDC director overrides advisory panel, recommends Pfizer COVID boosters for front-line workers
Cue Health kicks off $200M IPO to expand portable diagnostics: ‘We’re way more than a COVID-19 testing company’
Facing class action lawsuit over insulin pricing, Novo Nordisk inks $100M settlement with disgruntled investors
Humana, Centene sue Merck over 'pay for delay' deal for cholesterol drugs
Ransomware attacks impact patient care, including increased mortality rates, report finds
If CytoDyn can't get leronlimab approved, these shareholders have a bold plan to tap Big Pharma
FDA's ongoing review of accelerated cancer approvals targets 2 drugs from Secura and Aurobindo
After stints at Kite and Amgen, Roivant's Sidhu heads to Brooklyn ImmunoTherapeutics as CMO

Featured Story

CDC director overrides advisory panel, recommends Pfizer COVID boosters for front-line workers

By Dave Muoio

Industry groups have so far applauded the CDC's unusual move, saying the boosters give extra protection to the nation's healthcare workers at a time when it's needed most.

Cue Health kicks off $200M IPO to expand portable diagnostics: ‘We’re way more than a COVID-19 testing company’

By Andrea Park

Right on cue, another diagnostics-focused startup has made the transition to a public company. The latest to join the droves of medtechs flooding the stock market is Cue Health, which has so far found its greatest success in developing a portable COVID-19 test kit—but has big dreams of bringing the handheld system into every corner of healthcare.

Facing class action lawsuit over insulin pricing, Novo Nordisk inks $100M settlement with disgruntled investors

By Kevin Dunleavy

Resolving a lawsuit that was in the courts for four years, Novo Nordisk has agreed to a $100 million settlement with investors who argued that the company made untrue statements about insulin pricing pressures.

Humana, Centene sue Merck over 'pay for delay' deal for cholesterol drugs

By Paige Minemyer

Humana and Centene Corporation have filed suit against Merck, alleging that the drugmaker ran a "monopolistic scheme" to delay generic challengers to its cholesterol medications Zetia and Vytorin.

Ransomware attacks impact patient care, including increased mortality rates, report finds

By Anastassia Gliadkovskaya

Besides nearly a quarter of respondents reporting increased patient mortality rates following an attack, they also report longer stays, delays in procedures that lead to poor outcomes, more patient transfers and increased complications from medical procedures.

If CytoDyn can't get leronlimab approved, these shareholders have a bold plan to tap Big Pharma

By Annalee Armstrong

If CytoDyn’s management can’t get their lead treatment approved, a group of very optimistic investors want to give it a try. After weeks of very public infighting at the Vancouver, Washington-based biotech, a stockholder group has come forward with a strategic plan to get leronlimab approved in a cancer indication.

FDA's ongoing review of accelerated cancer approvals targets 2 drugs from Secura and Aurobindo

By Angus Liu

The FDA initially targeted immunotherapies in its industry-wide review of accelerated drug approvals in oncology that failed to deliver in confirmatory trials. But the agency isn’t stopping there. Blood cancer indications for Secura Bio’s Farydak and Aurobindo Pharma subsidiary Acrotech Biopharma’s Marqibo are now facing scrutiny.

After stints at Kite and Amgen, Roivant's Sidhu heads to Brooklyn ImmunoTherapeutics as CMO

By Kyle LaHucik

After about a year at Roivant Sciences, Roger Sidhu, M.D., is headed for the exit to take up the chief medical officer post at a smaller biotech, Brooklyn ImmunoTherapeutics.

PM Tracker